15
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      Are you tired of sifting through news that doesn't interest you?
      Personalize your Karger newsletter today and get only the news that matters to you!

      Sign up

      • Record: found
      • Abstract: found
      • Article: found

      Evaluation of Topical Drug Treatment in Psoriasis

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: During the last decade important innovations in the topical treatment of psoriasis have been accomplished, and important investments in new drug development for psoriasis are planned. Methods: A survey was conducted among psoriatic patients in order to quantify the present mode of use of topical drugs by the patients, the mode of prescription by their doctors and the compatibility of actual use and instructions to the patients. Results: Major observations are: The distribution of lesions, in particular on the scalp and soles, justifies major investments in the development of a treatment at these locations. Calcipotriol and topical corticosteroids (classes III and IV) are by far the most frequently prescribed topical drugs. Although at the time of investigation, calciopotriol was only available as ointment in the Netherlands, it is prescribed twice as often as clobetasol which is both available as an ointment and cream. Dermatologists are responsible for approximately 2/3 and general practitioners for 1/3 of the prescriptions. The prescription by general practitioners also comprises the continuation of prescriptions by the dermatologist. The duration of topical treatment is unrestricted in the majority of patients. However, use of up to 8 weeks is only seldom practised. Therefore, long-term safety and efficacy data of these drugs are mandatory for any topical treatment. Although twice daily treatment was advised in 50% of all patients, this treatment frequency was followed in only 33% of them. Greasiness accounted for non-compliance in 11% of the patients. Less frequent applications were desired by 38% of the patients, including patients on a once-a-day regimen. Most patients preferred the cream formulation. However, the variability of the expression of psoriasis (dry cracked exudative or superficially scaling lesions) required the availability of both cream and ointment formulations. Conclusion: An optimal treatment of psoriasis requires a spectrum of topical drugs and their formulations in different vehicles.

          Related collections

          Most cited references3

          • Record: found
          • Abstract: not found
          • Article: not found

          Treatment of psoriasis.

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Kimura's disease associated with ulcerative colitis: detection of IL-5 mRNA expression of peripheral blood mononuclear cells and colon lesion.

              Kimura's disease is considered to be a Th2 type allergic reaction based on the presence of eosinophilia and IgE hyperimmunoglobulinemia. We report a 26-year-old Japanese male with this disorder associated with ulcerative colitis. IL-5 is a selective stimulator for the production of eosinophilia and is considered to play an important role in Kimura's disease. IL-5 mRNA from peripheral blood mononuclear cells and the colon lesion were detected by the reverse-transcriptase polymerase chain reaction method, indicating that IL-5 can also be of importance in ulcerative colitis.
                Bookmark

                Author and article information

                Journal
                DRM
                Dermatology
                10.1159/issn.1018-8665
                Dermatology
                S. Karger AG
                1018-8665
                1421-9832
                1998
                1998
                13 July 1998
                : 197
                : 1
                : 31-36
                Affiliations
                aDepartment of Dermatology, University Hospital Nijmegen, bDepartment of Epidemiology, University of Nijmegen, and cLEO Pharmaceutical Products BV, Weesp, The Netherlands
                Article
                17972 Dermatology 1998;197:31–36
                10.1159/000017972
                9693182
                512b436f-d348-4044-ad56-1a3547cf1d46
                © 1998 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                Page count
                Pages: 6
                Categories
                Pharmacology and Treatment

                Oncology & Radiotherapy,Pathology,Surgery,Dermatology,Pharmacology & Pharmaceutical medicine
                Dithranol,Tar,Calcipotriol,Ointment,Corticosteroids,Vitamin D3 ,Cream

                Comments

                Comment on this article